According to the latest study from BCC Research, "Global Cancer Therapeutics Market: Emphasis on Recurrent and Metastatic ...

Cancer: «forgotten» cells go on the offensive. UNIGE Immunologists have discovered the yet unsuspected anti-tumour potential ...

In the fight against cancer, immunotherapy—which aims to boost the body's natural defenses against cancer—is experiencing ...

TCEs are a novel form of antibody with distinctive Fab and Fc structures. Their mechanism of action involves one Fab binding to a specific tumor-associated antigen (TAA), and the other Fab attaching ...

That means, if Harry were a real-life patient, there’d be reason to believe his disease was advanced. “It could still be local”—which means it hasn’t yet spread beyond the prostate—“but it would take ...

The report indicates >25 clinical trials, with the highest phase being Phase II/III as of June 2025. The US and China lead with >20 trials. Gamma Delta T Cell therapy, promising in treating blood ...

Nanostics has secured funding from Genome Canada and Genome Alberta to expedite the ClarityDX Prostate test integration into ...

The interplay between viruses and tumor progression represents a critical area of study, as certain oncogenic viruses, such as HPV, EBV, and HBV, are known ...

The firm hopes to overcome common dose-limiting toxicities with its PSMA-targeted radiotherapy while boosting potency versus competitors.

Anixa Biosciences advances CAR T-cell therapy for recurrent ovarian cancer, targeting FSHR with promising safety and efficacy ...

(UroToday.com) The 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in New Orleans, LA, was host to an Oncology Discovery and Translational session. Dr. Huipan Liu ...